Neuregenix   Report issue

For profit Phase 2
Founded: Birmingham United Kingdom (2007)

Organization Overview

First Clinical Trial
2019
NCT03705390
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Neuregenix

Active Ingredients

Drugs in Phase 2 Trials (1)

dextran (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Amyotrophic Lateral Sclerosis (Phase 2)

Motor Neuron Disease (Phase 2)

Sclerosis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1